NEWS

Kaken Pharmaceutical and Axcelead DDP
Begin Collaboration to Create Innovative New Drugs

2023.01.11

PDF   Kaken Pharmaceutical Co., Ltd. (“Kaken”, Head Office: Bunkyo-ku, Tokyo; President and Representative Director, Hiroyuki Horiuchi) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”, Head Office: Fujisawa, Kanagawa; President and CEO, Yoshinori Ikeura) announced that the companies have entered into an agreement to collaborate on creating innovative new drugs. As part of initiatives that […]

  • News Release

ThinkCyte and Axcelead DDP collaborate to advance novel phenotypic screening methods

2022.12.27

PDF Tokyo and Fujisawa, Japan. December 27, 2022: ThinkCyte and Axcelead Drug Discovery Partners (DDP) announced a research partnership focused on developing new approaches to screen candidate drugs for treating human diseases. The partnership will combine Ghost Cytometry1), ThinkCyte’s AI-driven cell characterization and sorting technology, with Axcelead DDP’s phenotypic screening techniques2) and its diverse compound […]

  • News Release

Axcelead Drug Discovery Partners, Inc. has become a certified provider of spatial transcriptomics technology, Visium, from 10x Genomics

2022.11.14

We’re delighted to announce that we have received official certification from 10x Genomics as a Certified Service Provider (CSP) of Visium, a spatial transcriptomics technology. The CSP status is awarded to providers who are able to deliver Visium services at a quality level that meets or exceeds a certain standard. Spatial transcriptomics enables simultaneous and […]

  • Information

Axcelead DDP and Knowledge Palette Enter into a Collaborative Research Contract on Gene Expression Analysis Concerning Drug-Resistant Cancer

2022.11.02

PDF Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura) and Knowledge Palette, Inc. (headquarters: Kawasaki, Kanagawa; Co-Founders and Representative Directors: Hiroki Danno and Masakazu Fukuda) have entered into a collaborative research contract on gene expression analysis for drug-resistant cancer. In this collaborative research project, the companies will collaborate to discover specific cell […]

  • News Release

Dr. Hideo Fukui will chair the international symposium about new modalities at the American College of Toxicology 2022 annual meeting.

2022.10.20

The American College of Toxicology 2022 annual meeting will be held in Denver on November 13 to 16, and an international symposium between the US, EU and Japan will be held on Tuesday, November 15, 2022. Dr. Hideo Fukui, a Senior Director of Axcelead Drug Discovery Partners, Inc. will chair the session “Antibody-Drug Conjugates, Exosomes: […]

  • News Release

Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch Drug Discovery Collaboration in Neuroscience

2022.10.05

PDF October 5, 2022 – Axcelead Drug Discovery Partners Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announces a drug discovery collaboration with Acadia Pharmaceuticals Inc. (HQ: San Diego, CA, USA; hereinafter referred to as “Acadia”) to generate innovative medicines in the neuroscience area. The parties will engage in research programs to […]

  • News Release

Epigeneron and Axcelead DDP singed a master collaboration agreement on drug discovery research for novel drug targets

2022.09.01

The PDF for the print Epigeneron Inc., (Headquarters: Chuo-ku, Tokyo, President: Tetsuya Mishima, “Epigeneron”) and Axcelead Drug Discovery Partners, Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture, President: Yoshinori Ikeura, “Axcelead DDP”) have entered into a master collaboration agreement on drug discovery research for novel drug targets.  Epigeneron has a new and unique technology to identify novel […]

  • News Release
  • Partnership・Collaboration

Perseus Proteomics and Axcelead DDP launch a collaboration for an antibody drug discovery support service

2022.08.19

PDF Perseus Proteomics Inc. (Head office: Meguro, Tokyo; President & CEO: Takuya Yokokawa, “Perseus”) and Axcelead Drug Discovery Partners Inc. (Head office: Fujisawa, Kanagawa; President & CEO: Yoshinori Ikeura, “Axcelead DDP”) today announced a collaboration in the antibody drug discovery support service. Perseus is generating antibody-based transformative therapeutics. Perseus has the proprietary and unique screening […]

  • News Release
  • antibody
  • Partnership・Collaboration

ARCALIS and Axcelead DDP Announce Collaboration to Provide Integrated Drug Discovery Support Service for mRNA Therapeutics

2022.07.20

PDF TOKYO, JAPAN, 20 JULY 2022: ARCALIS Inc. (Head office: Kashiwa, Chiba; President & CEO: Tomoyuki Fujisawa; “ARCALIS”) and Axcelead Drug Discovery Partners Inc. (Head office: Fujisawa, Kanagawa; President & CEO: Yoshinori Ikeura; “Axcelead DDP”), both are subsidiary of  Axcelead Inc. (Head office: Minato-ku, Tokyo; President & CEO: Tomoyuki Fujisawa; “Axcelead”), today announced a collaboration […]

  • News Release
  • mRNA
  • Partnership・Collaboration

Axcelead DDP and Knowledge Palette
Entered into a Collaborative Research Contract for Establishment of a
New Evaluation Platform UsingAxcelead DDP’s Compound Libraries and Large-Scale Transcriptome Analysis Technologies

2022.03.31

PDF Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura; hereinafter referred to as “Axcelead DDP”) and Knowledge Palette, Inc. (headquarters: Kawasaki, Kanagawa; Co-founder, Representative Director: Hiroki Danno, Masakazu Fukuda; hereinafter referred to as “Knowledge Palette”) announce that both companies have entered into a collaborative research contract for establishment of a new evaluation […]

  • News Release
  • Partnership・Collaboration

IP Generator, Axcelead, and Axcelead Drug Discovery Partners Signed a Comprehensive Business Alliance Agreement

2022.01.17

The PDF for the print To Establish a Platform for the Efficient and High-quality Drug Discovery Aiming to Resolve Social Issues by Reducing Medical Costs On January 11th, IP Generator, Inc. (hereafter “IPG”), Axcelead, Inc. (hereafter “Axcelead”) and Axcelead Drug Discovery Partners, Inc. (hereafter “Axcelead DDP”) (those three companies are collectively called “Parties”) have signed […]

  • News Release
  • Partnership・Collaboration

Hitachi and Axcelead DDP Launch Manufacturing Process Development Support Service for Cell Therapy and Gene Therapy

2021.12.15

Supporting optimization of product development and manufacturing with automation and quality assessment Tokyo, December 15, 2021 — Hitachi, Ltd. (TSE:6501, “Hitachi”) and Axcelead Drug Discovery Partners Inc. (“Axcelead DDP”) announced today that they launch a manufacturing process development support service for cell therapy and gene therapy from December 16.This service enables evaluation of cell quality […]

  • News Release
  • cell therapy
  • gene therapy
  • Partnership・Collaboration

Axcelead Drug Discovery Partners was rated as “Excellent” by Japan Agency for Medical Research and Development (AMED)* in a program for “Drug Discovery Seeds Development”

2021.11.25

Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) has supported 24 research projects aiming at new drug development in an infrastructure program for “Drug Discovery Seeds Development ” since 2017. This program is one of initiatives in AMED to incubate drug discovery seeds originated in academic research organizations. In this program, Axcelead DDP has worked as […]

  • News Release

xFOREST Therapeutics, Axcelead DDP and Kyowa Kirin Initiated an Collaboration in RNA Structures Targeted Drug Discovering

2021.11.01

Tokyo, Japan, October ##, 2021 — xFOREST Therapeutics Co., Ltd. (Headquarter: Kamigyo-ku, Kyoto, Japan, President and CEO: Shunichi Kashida, “xFOREST”), Axcelead Drug Discovery Partners Inc. (Headquarter: Fujisawa, Kanagawa, President: Yoshinori Ikeura, “Axcelead DDP”), and Kyowa Kirin Co., Ltd. (Headquarter: Chiyoda-ku, Tokyo, TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) announce that the three companies have […]

  • News Release
  • Partnership・Collaboration

Axcelead DDP participates in “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan”, as a joint research institute

2021.10.25

We are pleased to announce that Axcelead Drug Discovery Partners Inc., (Headquarters: Fujisawa, Kanagawa, JAPAN, CEO: Yoshinori Ikeura, hereinafter “Axcelead DDP”) will participate as a joint research institution to support “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan” led by the National Cancer Center Hospital East (Location: […]

  • News Release

Axcelead has entered into a comprehensive agreement including transfer of key drug discovery platforms with a major Japanese pharmaceutical company

2021.10.18

Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa, Kanagawa, President, CEO: Yoshinori Ikeura; Axcelead) announces that the company has strengthened the platforms including high-throughput screening (HTS), high-throughput ADME (metabolism & pharmacokinetics) and TOX (safety) studies (HT-ADMET), based on a comprehensive business transfer agreement with a major Japanese pharmaceutical company (hereinafter, referred to as “the pharmaceutical company”). […]

  • News Release

Evommune and Axcelead Drug Discovery Partners Launch A Collaboration On A PKCtheta Program To Kick-off Evommune’s Inflammation Pipeline

2020.12.10

Inhibition of PKCtheta as a therapeutic target has the potential to treat multiple inflammatory diseases Los Altos, California, USA and Fujisawa, Kanagawa, Japan – Dec. 10, 2020 – Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, and Axcelead Drug Discovery Partners, Inc. (Axcelead), a Japanese solution provider in drug discovery research, […]

  • News Release
  • A-Hit
  • Partnership・Collaboration

Axcelead and Kyowa Kirin Started an Innovative
Collaboration in Small-Molecule Drug Development

2020.10.02

Tokyo, Japan, October 2, 2020 —Axcelead Drug Discovery Partners Inc.(Axcelead, President: Yoshinori Ikeura)and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) announce that the companies have started collaboration on the development of innovative small-molecule drugs based on a novel drug discovery technology platform. By integrating Axcelead ‘s broad range of small-molecule […]

  • News Release
  • New Core Technologies
  • Partnership・Collaboration
  • Small molecule

Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce
joint research in ​​CNS indications

2020.06.17

June 29,2020- Otsuka Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Makoto Inoue; Otsuka Pharmaceutical) and Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa, Kanagawa, President: Yoshinori Ikeura; Axcelead) announce a collaborative drug discovery research using the Axcelead Hit-identified Target (A-HiT) project* in the area of central nervous system diseases. Axcelead is the first comprehensive integrated […]

  • News Release
  • A-Hit
  • Partnership・Collaboration

PassPort Technologies and Axcelead Drug Discovery Partners

2019.10.01

Enter a comprehensive collaborative partnership in the field of drug discovery service using PassPort System, a new active transdermal drug delivery technology Contribute to maximizing R&D pipeline value though providing a new modality PassPort Technologies, Inc. (President and CEO: Tomoyuki Fujisawa, California, USA) (PPTI) and Axcelead Drug Discovery Partners Co., Ltd. (President: Yoshinori Ikeura, Fujisawa, […]

  • News Release
  • Biologics
  • Mid-size molecule
  • Partnership・Collaboration

Fujifilm and Axcelead Drug Discovery Partners begin collaborating
to advance drug discovery solutions using iPSCs

2019.07.10

To enhance the Process of Research and Development of Drug Candidates Tokyo/Kanagawa, July 10, 2019 ―FUJIFILM Corporation (President: Kenji Sukeno; Fujifilm) and Axcelead Drug Discovery Partners Inc. (President: Yoshinori Ikeura; Axcelead) announced a collaboration to provide customers with a human induced pluripotent stem cell (iPSC)-based integrated platform for drug discovery solutions. By combining Fujifilm’s iPSC-derived […]

  • News Release
  • Cardiotoxicity Assessment
  • Partnership・Collaboration

Transfer of All Axcelead Shares to Whiz Partners DDG Fund Completed

2019.04.01

April 1, 2019 – Whiz Partners Inc. (hereinafter, “Whiz”), headquartered in Minato Ward, Tokyo, announced that it has completed an investment-in-kind to the “Drug Discovery Gateway Investment Limited Partnership” (hereinafter, “DDG Fund”) of issued Axcelead Drug Discovery Partners Inc. (hereinafter, “Axcelead”) shares held by Takeda Pharmaceutical Co., Ltd. (hereinafter, “Takeda”), headquartered in Chuo Ward, Osaka. […]

  • News Release
  • About Us

Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9 License Agreement

2018.10.17

Fujisawa, Japan and Dublin, Ireland, October 4, 2018 – Axcelead Drug Discovery Partners, Inc.(hereinafter referred to as “Axcelead”) and ERS Genomics Limited (hereinafter referred to as “ERS Genomics”) announced today a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering. […]

  • News Release
  • Genetically modified mouse/rat
  • License

Announcement on starting preparation to become a company independent from Takeda

2018.08.03

We are pleased to announce that Axcelead Drug Discovery Partners Inc. (“Axcelead”) preparation to become a company independent from Takeda Pharmaceutical Company Limited (“Takeda”) as a core company of “Drug Discovery Gateway Investment Limited Partnership” (“DDG Fund”). Under the terms of the agreement between Takeda and Japan-based Alternative Asset Management Firm, Whiz Partners, Inc. (“Whiz”), […]

  • News Release
  • About Us

Announcement of Start of Business Partnership between Axcelead and LAP&P for Modeling and Simulation of Drug Discovery

2018.05.30

We are pleased to announce that Axcelead Drug Discovery Partners, Inc. (Yoshinori Ikeura, President; Headquarters: Fujisawa-shi, Kanagawa, Japan; hereinafter referred to as “Axcelead”) and Leiden Experts on Advanced Pharmacokinetics & Pharmacodynamics Consultants BV (Henk-Jan Drenth, Managing Director; Headquarters: Leiden, the Netherlands; hereinafter referred to as “LAP&P”) decided to develop a business partnership for services provided […]

  • News Release
  • Clinical PK/PD Prediction
  • Partnership・Collaboration